The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Bioequivalent Peptide Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Bioequivalent Peptide Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029

Publishing Date : Sep, 2023

License Type :
 

Report Code : 1772610

No of Pages : 105

Ask Your Query

Synopsis
The global Bioequivalent Peptide Drugs market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.

A bioequivalent peptide drug is one that has similar structure and function, and exhibits similar pharmacokinetic and pharmacodynamic properties in vivo to the original brand drug or an approved reference product. These drugs are usually synthesized through genetic recombination technology and undergo rigorous research and development and approval procedures.

The development and production of bioequivalent peptide drugs usually requires detailed comparison and analysis, including in vitro and in vivo experimental evaluation, and comparison of clinical trial data. Bioequivalent peptide drugs have a wide range of applications in drug replacement, therapeutic expansion, and biosimilars.

The Global Info Research report includes an overview of the development of the Bioequivalent Peptide Drugs industry chain, the market status of Short Bowel Syndrome (Teriparatide(Forteo), Teduglutide(Gattex)), Osteoporosis (Teriparatide(Forteo), Teduglutide(Gattex)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Bioequivalent Peptide Drugs.

Regionally, the report analyzes the Bioequivalent Peptide Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Bioequivalent Peptide Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Bioequivalent Peptide Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Bioequivalent Peptide Drugs industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (Units), revenue generated, and market share of different by Type (e.g., Teriparatide(Forteo), Teduglutide(Gattex)).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Bioequivalent Peptide Drugs market.

Regional Analysis: The report involves examining the Bioequivalent Peptide Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Bioequivalent Peptide Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Bioequivalent Peptide Drugs:

Company Analysis: Report covers individual Bioequivalent Peptide Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Bioequivalent Peptide Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Short Bowel Syndrome, Osteoporosis).

Technology Analysis: Report covers specific technologies relevant to Bioequivalent Peptide Drugs. It assesses the current state, advancements, and potential future developments in Bioequivalent Peptide Drugs areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Bioequivalent Peptide Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Bioequivalent Peptide Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type

  • Teriparatide(Forteo)
  • Teduglutide(Gattex)
  • Liraglutide(Victoza)

Market segment by Application

  • Short Bowel Syndrome
  • Osteoporosis
  • Type 2 Diabetes
  • Others

Major players covered

  • Eli Lilly and Company
  • Alvogen
  • Pfenex
  • HEC Pharm
  • Bachem
  • Bharat Pharmaceuticals
  • Kingpep Biotechnology
  • Ambio Pharmaceuticals
  • Jiangsu Sinopep Allsino Biopharmaceutical
  • Shanghai Shyndec Pharmaceutical
  • Shenzhen Salubris Pharmaceuticals
  • Shanghai United Cell Biotechnology
  • Shenzhen JYMed Technology
  • Wuxi Asiapeptide Biotechnology

Market segment by region, regional analysis covers

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
  • South America (Brazil, Argentina, Colombia, and Rest of South America)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Bioequivalent Peptide Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Bioequivalent Peptide Drugs, with price, sales, revenue and global market share of Bioequivalent Peptide Drugs from 2018 to 2023.
Chapter 3, the Bioequivalent Peptide Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bioequivalent Peptide Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Bioequivalent Peptide Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Bioequivalent Peptide Drugs.
Chapter 14 and 15, to describe Bioequivalent Peptide Drugs sales channel, distributors, customers, research findings and conclusion.

Index

1 Market Overview
1.1 Product Overview and Scope of Bioequivalent Peptide Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Bioequivalent Peptide Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Teriparatide(Forteo)
1.3.3 Teduglutide(Gattex)
1.3.4 Liraglutide(Victoza)
1.4 Market Analysis by Application
1.4.1 Overview: Global Bioequivalent Peptide Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Short Bowel Syndrome
1.4.3 Osteoporosis
1.4.4 Type 2 Diabetes
1.4.5 Others
1.5 Global Bioequivalent Peptide Drugs Market Size & Forecast
1.5.1 Global Bioequivalent Peptide Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Bioequivalent Peptide Drugs Sales Quantity (2018-2029)
1.5.3 Global Bioequivalent Peptide Drugs Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Eli Lilly and Company
2.1.1 Eli Lilly and Company Details
2.1.2 Eli Lilly and Company Major Business
2.1.3 Eli Lilly and Company Bioequivalent Peptide Drugs Product and Services
2.1.4 Eli Lilly and Company Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Eli Lilly and Company Recent Developments/Updates
2.2 Alvogen
2.2.1 Alvogen Details
2.2.2 Alvogen Major Business
2.2.3 Alvogen Bioequivalent Peptide Drugs Product and Services
2.2.4 Alvogen Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Alvogen Recent Developments/Updates
2.3 Pfenex
2.3.1 Pfenex Details
2.3.2 Pfenex Major Business
2.3.3 Pfenex Bioequivalent Peptide Drugs Product and Services
2.3.4 Pfenex Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfenex Recent Developments/Updates
2.4 HEC Pharm
2.4.1 HEC Pharm Details
2.4.2 HEC Pharm Major Business
2.4.3 HEC Pharm Bioequivalent Peptide Drugs Product and Services
2.4.4 HEC Pharm Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 HEC Pharm Recent Developments/Updates
2.5 Bachem
2.5.1 Bachem Details
2.5.2 Bachem Major Business
2.5.3 Bachem Bioequivalent Peptide Drugs Product and Services
2.5.4 Bachem Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Bachem Recent Developments/Updates
2.6 Bharat Pharmaceuticals
2.6.1 Bharat Pharmaceuticals Details
2.6.2 Bharat Pharmaceuticals Major Business
2.6.3 Bharat Pharmaceuticals Bioequivalent Peptide Drugs Product and Services
2.6.4 Bharat Pharmaceuticals Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Bharat Pharmaceuticals Recent Developments/Updates
2.7 Kingpep Biotechnology
2.7.1 Kingpep Biotechnology Details
2.7.2 Kingpep Biotechnology Major Business
2.7.3 Kingpep Biotechnology Bioequivalent Peptide Drugs Product and Services
2.7.4 Kingpep Biotechnology Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Kingpep Biotechnology Recent Developments/Updates
2.8 Ambio Pharmaceuticals
2.8.1 Ambio Pharmaceuticals Details
2.8.2 Ambio Pharmaceuticals Major Business
2.8.3 Ambio Pharmaceuticals Bioequivalent Peptide Drugs Product and Services
2.8.4 Ambio Pharmaceuticals Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Ambio Pharmaceuticals Recent Developments/Updates
2.9 Jiangsu Sinopep Allsino Biopharmaceutical
2.9.1 Jiangsu Sinopep Allsino Biopharmaceutical Details
2.9.2 Jiangsu Sinopep Allsino Biopharmaceutical Major Business
2.9.3 Jiangsu Sinopep Allsino Biopharmaceutical Bioequivalent Peptide Drugs Product and Services
2.9.4 Jiangsu Sinopep Allsino Biopharmaceutical Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Jiangsu Sinopep Allsino Biopharmaceutical Recent Developments/Updates
2.10 Shanghai Shyndec Pharmaceutical
2.10.1 Shanghai Shyndec Pharmaceutical Details
2.10.2 Shanghai Shyndec Pharmaceutical Major Business
2.10.3 Shanghai Shyndec Pharmaceutical Bioequivalent Peptide Drugs Product and Services
2.10.4 Shanghai Shyndec Pharmaceutical Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Shanghai Shyndec Pharmaceutical Recent Developments/Updates
2.11 Shenzhen Salubris Pharmaceuticals
2.11.1 Shenzhen Salubris Pharmaceuticals Details
2.11.2 Shenzhen Salubris Pharmaceuticals Major Business
2.11.3 Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Product and Services
2.11.4 Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Shenzhen Salubris Pharmaceuticals Recent Developments/Updates
2.12 Shanghai United Cell Biotechnology
2.12.1 Shanghai United Cell Biotechnology Details
2.12.2 Shanghai United Cell Biotechnology Major Business
2.12.3 Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Product and Services
2.12.4 Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Shanghai United Cell Biotechnology Recent Developments/Updates
2.13 Shenzhen JYMed Technology
2.13.1 Shenzhen JYMed Technology Details
2.13.2 Shenzhen JYMed Technology Major Business
2.13.3 Shenzhen JYMed Technology Bioequivalent Peptide Drugs Product and Services
2.13.4 Shenzhen JYMed Technology Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Shenzhen JYMed Technology Recent Developments/Updates
2.14 Wuxi Asiapeptide Biotechnology
2.14.1 Wuxi Asiapeptide Biotechnology Details
2.14.2 Wuxi Asiapeptide Biotechnology Major Business
2.14.3 Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Product and Services
2.14.4 Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Wuxi Asiapeptide Biotechnology Recent Developments/Updates
3 Competitive Environment: Bioequivalent Peptide Drugs by Manufacturer
3.1 Global Bioequivalent Peptide Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Bioequivalent Peptide Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Bioequivalent Peptide Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Bioequivalent Peptide Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Bioequivalent Peptide Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Bioequivalent Peptide Drugs Manufacturer Market Share in 2022
3.5 Bioequivalent Peptide Drugs Market: Overall Company Footprint Analysis
3.5.1 Bioequivalent Peptide Drugs Market: Region Footprint
3.5.2 Bioequivalent Peptide Drugs Market: Company Product Type Footprint
3.5.3 Bioequivalent Peptide Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Bioequivalent Peptide Drugs Market Size by Region
4.1.1 Global Bioequivalent Peptide Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Bioequivalent Peptide Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Bioequivalent Peptide Drugs Average Price by Region (2018-2029)
4.2 North America Bioequivalent Peptide Drugs Consumption Value (2018-2029)
4.3 Europe Bioequivalent Peptide Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Bioequivalent Peptide Drugs Consumption Value (2018-2029)
4.5 South America Bioequivalent Peptide Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Bioequivalent Peptide Drugs Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Bioequivalent Peptide Drugs Sales Quantity by Type (2018-2029)
5.2 Global Bioequivalent Peptide Drugs Consumption Value by Type (2018-2029)
5.3 Global Bioequivalent Peptide Drugs Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Bioequivalent Peptide Drugs Sales Quantity by Application (2018-2029)
6.2 Global Bioequivalent Peptide Drugs Consumption Value by Application (2018-2029)
6.3 Global Bioequivalent Peptide Drugs Average Price by Application (2018-2029)
7 North America
7.1 North America Bioequivalent Peptide Drugs Sales Quantity by Type (2018-2029)
7.2 North America Bioequivalent Peptide Drugs Sales Quantity by Application (2018-2029)
7.3 North America Bioequivalent Peptide Drugs Market Size by Country
7.3.1 North America Bioequivalent Peptide Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Bioequivalent Peptide Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Bioequivalent Peptide Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Bioequivalent Peptide Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Bioequivalent Peptide Drugs Market Size by Country
8.3.1 Europe Bioequivalent Peptide Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Bioequivalent Peptide Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Bioequivalent Peptide Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Bioequivalent Peptide Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Bioequivalent Peptide Drugs Market Size by Region
9.3.1 Asia-Pacific Bioequivalent Peptide Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Bioequivalent Peptide Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Bioequivalent Peptide Drugs Sales Quantity by Type (2018-2029)
10.2 South America Bioequivalent Peptide Drugs Sales Quantity by Application (2018-2029)
10.3 South America Bioequivalent Peptide Drugs Market Size by Country
10.3.1 South America Bioequivalent Peptide Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Bioequivalent Peptide Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Bioequivalent Peptide Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Bioequivalent Peptide Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Bioequivalent Peptide Drugs Market Size by Country
11.3.1 Middle East & Africa Bioequivalent Peptide Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Bioequivalent Peptide Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Bioequivalent Peptide Drugs Market Drivers
12.2 Bioequivalent Peptide Drugs Market Restraints
12.3 Bioequivalent Peptide Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Bioequivalent Peptide Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Bioequivalent Peptide Drugs
13.3 Bioequivalent Peptide Drugs Production Process
13.4 Bioequivalent Peptide Drugs Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Bioequivalent Peptide Drugs Typical Distributors
14.3 Bioequivalent Peptide Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Published By : GlobalInfoResearch

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock